Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01050855 · ClinicalTrials.gov registry record · Phase 2
Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders
A Phase 2 study of Hemoglobinopathies and Immunodeficiencies, sponsored by Children's Hospital of Philadelphia.
- Active
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT01050855: Active Phase 2 study of Hemoglobinopathies and Immunodeficiencies, sponsored by Children's Hospital of Philadelphia.
NCT01050855 is a Phase 2 study of Hemoglobinopathies and Immunodeficiencies that is active but no longer recruiting, run by Children's Hospital of Philadelphia. The registered enrollment target is 75 participants, below the 1,799-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01050855, a Phase 2 study of Hemoglobinopathies and Immunodeficiencies, is active but no longer recruiting, sponsored by Children's Hospital of Philadelphia.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase II pilot study to evaluate engraftment and toxicity of patients with non-malignant diseases using a reduced intensity conditioning regimen in the setting of allogeneic transplant for non malignant diseases. Bone Marrow or cord blood will be acceptable as a stem cell source. Recently, reduced intensity conditioning (RIC) regimens have been used for both adult patients with leukemias and pediatric patients with non-malignant diseases. These regimens are better tolerated, resulting in less transplant related morbidity and mortality. Stable mixed chimerism, while insufficient for eradication of leukemias, may be sufficient to cure patients with non-malignant diseases.
Primary Outcome
engraftment of patients with non-malignant disorders will be evaluated using a reduced-intensity conditioning regimen
Conditions Studied
Interventions
- DRUG RIC: Distal Campath
- DRUG RIC:Intermediate Campath
- DRUG RIC: Mini Busulfan
Study Locations (1)
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2008-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT01050855 still lists
NCT01050855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 1,799-participant average among 17 other Hemoglobinopathies trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Hemoglobinopathies appearing as the primary indexed condition, and to 3 interventions - of which RIC: Distal Campath is the first listed.
NCT01050855 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01050855 about?
NCT01050855 is a clinical study titled "Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders". This is a Phase II pilot study to evaluate engraftment and toxicity of patients with non-malignant diseases using a reduced intensity conditioning regimen in the setting of allogeneic transplant for non malignant diseases. Bone Marrow or cord blood will be acceptable as a stem cell source. Recently...
What is the current status of trial NCT01050855?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2008-01. Estimated completion is 2026-12.
What conditions does trial NCT01050855 study?
This clinical trial studies the following conditions: Hemoglobinopathies, Immunodeficiencies, Non Malignant Diseases.
What interventions are being tested in trial NCT01050855?
The interventions under investigation include: RIC: Distal Campath (DRUG), RIC:Intermediate Campath (DRUG), RIC: Mini Busulfan (DRUG).
Who is sponsoring clinical trial NCT01050855?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01050855 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemoglobinopathies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01050855's enrollment target sits among peer trials
75 3rd of 17 higher than 15 of 17 other Hemoglobinopathies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemoglobinopathies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
-
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
RECRUITING · Phase 2
-
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
COMPLETED · Phase 2
-
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
RECRUITING · Phase 1
-
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
RECRUITING · NA
-
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia